Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Penalty levied by SEBI...

    Penalty levied by SEBI on Jubilant Life Sciences reduced to Rs 5 lakh

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-08T09:30:51+05:30  |  Updated On 16 Aug 2021 3:01 PM IST

    "We have found that the appellant in... Jubilant Life Sciences would be liable for a penalty only on one count i.e. for non-disclosure of the China warning immediately. The penalty accordingly is reduced to Rs 5 lacs," the tribunal said.


    New Delhi: Drugmaker, Jubilant Life Sciences, which was slapped a fine of Rs 10 lakh by Securities Exchange Board of India (SEBI) for violating norms pertaining to price-sensitive information, will now have to pay Rs 5 lakh as the Securities Appellate Tribunal (SAT) recently reduced the penalty amount from Rs 10 lakh to Rs 5 lakh.


    Earlier this year, SEBI had imposed a total fine of Rs 50 lakh on Jubilant Life Sciences, its three promoter entities and a director for violation of norms pertaining to price-sensitive information. The company was found to have made delayed disclosure to the exchanges regarding price-sensitive information.


    Also Read: SEBI slaps Rs 50 lakh penalty on Jubilant Life Sciences and 4 others


    "We have found that the appellant in... Jubilant Life Sciences would be liable for a penalty only on one count i.e. for non-disclosure of the China warning immediately. The penalty accordingly is reduced to Rs 5 lacs," the tribunal said.


    The tribunal has upheld the fine imposed on the promoters and vice-president of the firm.


    SEBI had also levied a penalty of Rs 10 lakh each on the promoters Jubilant Stock Holding, Shyam Sunder Bhartia and Hari Shankar Bhartia as well as the firm's Senior Vice-President Amit Arora for trading in the shares while in possession of unpublished price-sensitive information.


    Sebi in its order passed in January 2018 concluded that Jubilant Life Sciences had violated the listing agreement, while the other four entities had contravened Prohibition of Insider Trading Regulations.


    The violations pertain to instances during 2013 and 2014.


    The drug firm had announced that one of its manufacturing facility in Quebec, Canada, had been issued a warning letter dated February 20, 2013, by the USFDA. The letter was received by vice-president (operations) of Jubilant HollisterStier (JHS), Canada, on February 22 and the same was informed to Shyam Bhartia, Hari Bhartia and Arora.


    However, the company made a delayed announcement about it only on February 27, according to SEBI.


    Besides, the USFDA served a warning letter dated November 27, 2013, to a manufacturing facility in Spokane, Washington. An announcement about the warning letter was made to the exchanges only on December 5, 2013, even as it was received by the company on December 1.


    Read Also: Jubilant Life Sciences appoints Alok Vaish as CFO, Key Managerial Personnel


    In another instance, Sebi had noted that China's commerce ministry on May 28, 2013, announced imposing provisional duties on JHS, as well as on other Indian producers and Japanese producers.


    While the Chinese ministry's decision was expected to have an impact on the JHS' business, the company made an announcement about the same only on July 25, 2013, with a delay of around two months, Sebi had said.


    Additionally, the drug firm had also received communication on February 25, 2014, from the USFDA, classifying its pharmaceutical manufacturing facility at Montreal, Canada as 'Acceptable'. However, an announcement in this regard was made only on February 27.


    However, the tribunal dismissed Sebi's reasoning for levying fine on the firm for disclosure regarding the Washington warning and Canada acceptance letter saying that "in our view, the disclosure was made at the earliest opportune moment by the appellant of the Washington warning".


    It said that the firm is liable to pay fine only on one count, for non-disclosure of the China warning immediately.

    Amit ArorachinafineJHSJubilant fineJubilant LifeJubilant Life Sciencespharmapharma newsProhibition of Insider Trading RegulationsSATSEBISecurities Appellate TribunalShyam Sunder BhartiaUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok